Breakdown | ||||
Mar 2025 | Mar 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.36B | 1.31B | 1.17B | 993.20M | 870.46M | Gross Profit |
748.96M | 691.55M | 615.10M | 505.50M | 397.84M | EBIT |
221.82M | 164.88M | 156.03M | 80.75M | 57.96M | EBITDA |
221.82M | 265.58M | 249.34M | 178.50M | 142.25M | Net Income Common Stockholders |
167.68M | 117.56M | 115.40M | 43.38M | 79.47M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
306.76M | 178.80M | 284.47M | 259.50M | 192.31M | Total Assets |
2.45B | 2.20B | 1.93B | 1.86B | 1.82B | Total Debt |
303.56M | 807.79M | 765.89M | 773.59M | 707.61M | Net Debt |
-3.21M | 628.99M | 481.42M | 514.09M | 515.30M | Total Liabilities |
1.63B | 1.24B | 1.12B | 1.11B | 1.09B | Stockholders Equity |
820.84M | 959.96M | 818.00M | 749.42M | 731.67M |
Cash Flow | Free Cash Flow | |||
142.45M | 115.45M | 162.87M | 75.75M | 71.77M | Operating Cash Flow |
181.72M | 181.75M | 273.06M | 172.26M | 108.81M | Investing Cash Flow |
-161.90M | -322.39M | -143.79M | -86.34M | -425.44M | Financing Cash Flow |
108.82M | 38.16M | -100.36M | -15.75M | 367.45M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $3.37B | 21.13 | 18.83% | ― | 3.95% | 44.09% | |
73 Outperform | $9.98B | 27.64 | 15.15% | 1.19% | 0.34% | 17.27% | |
70 Outperform | $14.43B | 27.34 | 11.77% | ― | 1.66% | 21.95% | |
68 Neutral | $49.36B | 32.86 | 5.97% | 2.42% | 5.84% | 15.12% | |
68 Neutral | $3.25B | ― | -4.62% | ― | 7.19% | -56.19% | |
58 Neutral | $5.30B | 37.80 | 3.48% | 1.13% | 0.29% | -48.98% | |
54 Neutral | $5.38B | 3.27 | -45.10% | 3.30% | 16.81% | 0.02% |
In May 2025, Haemonetics‘ Board of Directors approved a strategic market and regional alignment initiative aimed at enhancing operational performance and reducing costs. This initiative is expected to incur restructuring charges of approximately $20 million, with anticipated annual savings of $30 million upon completion by the end of fiscal 2027. The company reported strong financial results for fiscal 2025, with a 4% increase in annual revenue to $1.361 billion and significant improvements in earnings and cash flow. Despite a decline in fourth-quarter revenue, Haemonetics achieved record margin expansion and operating income growth, driven by its hospital business and strategic pricing initiatives.